The Evolving Treatment Landscape of Medullary Thyroid Cancer
Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M Vodopivec Kuri, Deborah Cosentini, Alfredo Berruti · 2023
Read The Evolving Treatment Landscape of Medullary Thyroid Cancer by Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M Vodopivec Kuri, Deborah Cosentini, Alfredo Berruti (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10781862.txt.
Description
Marta Laganà and five co-authors review treatment choices for an uncommon thyroid cancer in a 2023 opinion piece. Medullary thyroid cancer often hinges on one gene, RET, so gene testing steers the whole plan once the disease is advanced.
Two broad-spectrum targeted drugs are named as sound first choices, though one is now limited to patients with the gene change. Sharper drugs aimed only at RET may go first when the change is of certain kinds. After the broad drugs fail, one sharp drug is the named second step. Later lines fall back on trials or other targeted drugs. The authors also look ahead to next-generation RET drugs built to beat resistance, and to immune therapy for tumors with many mutations.
Catalog record
| CREATOR | Marta Laganà, Valentina Cremaschi, Andrea Alberti, Danica M Vodopivec Kuri, Deborah Cosentini, Alfredo Berruti |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |